title: Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.
abstract: The incretin effect on insulin secretion was investigated in 8 subjects with type 2 diabetes (T2D) and 8 with normal glucose tolerance (NGT), using 25, 75, and 125 g oral glucose tolerance tests (OGTT) and isoglycemic intravenous glucose infusions (IIGI). The ß-cell response was evaluated using a model embedding a dose-response (slope=glucose sensitivity), an early response (rate sensitivity), and potentiation (time-related secretion increase). The incretin effect, as OGTT/IIGI ratio, was calculated for each parameter. In NGT, the incretin effect on total secretion increased with dose (1.3 ± 0.1, 1.7 ± 0.2, 2.2 ± 0.2 fold of IIGI, P<0.0001), mediated by a dose-dependent increase of the incretin effect on glucose sensitivity (1.9 ± 0.4, 2.4 ± 0.4, 3.1 ± 0.4, P=0.005), and a dose-independent enhancement of the incretin effect on rate sensitivity (894 [1145], 454 [516], 783 [1259] pmol m(-2) L mmol(-1) above IIGI; median [interquartile range], P<0.0001). The incretin effect on potentiation also increased (0.97 ± 0.06, 1.45 ± 0.20, 1.24 ± 0.16, P<0.0001). In T2D, the incretin effect on total secretion (1.0 ± 0.1, 1.1 ± 0.1, 1.3 ± 0.1, P=0.004) and glucose sensitivity (1.2 ± 0.2, 1.3 ± 0.2, 2.0 ± 0.2, P=0.005) were impaired vs NGT; however, the incretin effect on rate sensitivity increased already at 25 g (269 [169], 284 [301], 193 [465] pmol m(-2) L mmol(-1) above IIGI; negligible IIGI rate sensitivity in T2D prevented the calculation of the fold increment). OGTT did not stimulate potentiation above IIGI (0.94 ± 0.04, 0.89 ± 0.06, 1.06 ± 0.09; P<0.01 vs NGT). In the whole group, the incretin effect was inversely associated with total secretion during IIGI, although systematically lower in T2D. In conclusion, 1) In NGT, glucose sensitivity and potentiation mediate the dose-dependent incretin effect increase; 2) In T2D, the incretin effect is blunted vs NGT, but rate sensitivity is enhanced at all loads; 3) Relatively lower incretin effect in NGT is associated with higher secretion during IIGI, suggesting that the reduced incretin effect does not result from ß-cell dysfunction.
authors.affiliation: Institute of Biomedical Engineering, National Research Council, Padova, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Mari
authors.forename: Jonatan I
authors.initials: JI
authors.lastname: Bagger
authors.forename: Ele
authors.initials: E
authors.lastname: Ferrannini
authors.forename: Jens J
authors.initials: JJ
authors.lastname: Holst
authors.forename: Filip K
authors.initials: FK
authors.lastname: Knop
authors.forename: Tina
authors.initials: T
authors.lastname: Vilsbøll
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D054795:Incretins / Q000502:physiology*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D054795:Incretins; D007328:Insulin
references.citation: Diabetes. 2010 May;59(5):1117-25
references.pmid: 20427697
references.citation: Diabetes Obes Metab. 2012 Jun;14(6):500-10
references.pmid: 22171657
references.citation: Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1159-66
references.pmid: 12388151
references.citation: Diabetes Care. 2003 Oct;26(10):2860-4
references.pmid: 14514592
references.citation: J Clin Endocrinol Metab. 2009 Dec;94(12):4679-87
references.pmid: 19837930
references.citation: Diabetes. 1994 Apr;43(4):535-9
references.pmid: 8138058
references.citation: J Clin Endocrinol Metab. 1986 Aug;63(2):492-8
references.pmid: 3522621
references.citation: Diabetologia. 2010 Apr;53(4):749-56
references.pmid: 20225397
references.citation: J Clin Endocrinol Metab. 2011 Mar;96(3):737-45
references.pmid: 21252240
references.citation: Diabetes. 1999 Oct;48(10):1979-86
references.pmid: 10512362
references.citation: Diabetes Obes Metab. 2008 Nov;10 Suppl 4:77-87
references.pmid: 18834435
references.citation: Diabetes Care. 2001 Mar;24(3):539-48
references.pmid: 11289482
references.citation: Regul Pept. 1984 Sep;9(1-2):35-46
references.pmid: 6505290
references.citation: Am J Physiol. 1979 Sep;237(3):E214-23
references.pmid: 382871
references.citation: J Clin Endocrinol Metab. 2005 Jan;90(1):493-500
references.pmid: 15483086
references.citation: Diabetes. 2003 Feb;52(2):380-6
references.pmid: 12540611
references.citation: Diabetes. 2003 Feb;52(2):470-80
references.pmid: 12540623
references.citation: Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1144-50
references.pmid: 16478775
references.citation: Diabetes. 2008 May;57(5):1340-8
references.pmid: 18162504
references.citation: Diabetes. 2002 Feb;51 Suppl 1:S221-6
references.pmid: 11815483
references.citation: Diabetologia. 1986 Jan;29(1):46-52
references.pmid: 3514343
references.citation: Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E532-7
references.pmid: 19531643